Takeda Pharmaceutical Company Limited to invest €40m in a new production facility at its Grange Castle site in Dublin.
The largest pharmaceutical company in Japan and a global industry leader, Takeda first set up operations in Ireland in 1997 manufacturing products for global markets. In 2002 Takeda chose Dublin as the location for its first active pharmaceutical ingredient (API) facility outside of Japan.
The standalone high containment production facility is an expansion of its existing Grange castle footprint, and will be dedicated to manufacturing its oncology product NINLAROTM for global markets. The investment will create approximately 40 new jobs.
Welcoming the new investment by Takeda, Minister for Jobs, Enterprise and Innovation, Minister Mitchell O’Connor said, “The pharma industry makes a huge contribution to the Irish economy in terms of jobs and exports, and is one of the fastest growing sectors.”
She added, “Takeda’s decision to manufacture their new cancer treatment in Ireland is a great win and vote of confidence in Ireland and it builds on our ongoing expansion of the sector here. I’m delighted that this investment will bring a further 40 jobs to the company’s existing Clondalkin facility.”
About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news.
Source: IDA Ireland